5 questions about first injection.
Pain varies by product, device, injection site and person. Some people feel only a brief pinch, while others have stinging or soreness. Follow the product's Instructions for Use. Contact the prescriber if pain is severe, lasts longer than expected or comes with increasing redness, swelling, warmth, drainage, hives or breathing problems.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Use only the route in the exact product label and prescription. Subcutaneous and intramuscular administration are not interchangeable, and a route used in an animal study or online protocol is not patient guidance.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Use the exact product’s Instructions for Use and the sites your clinician taught you. Approved products differ, and an unapproved product has no validated patient injection site.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Do not rely on internet reassurance for a prepared injection. Follow the device instructions; if you cannot prepare the prescribed dose as directed, contact the pharmacist or clinician before injecting.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Tell the prescriber before starting. Ask about an approved non-injectable alternative, an autoinjector, in-office teaching, or supervised administration. Do not practice with an unapproved product.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
← All FAQ topics | Browse all peptides
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify